Canadian CANNAINVESTOR Magazine August / September 2017 - Page 189

179

As we continue to add to our database with additional patient information, strain selection, quest-ionnaire scores from validated research tools (for anxiety, de-pression, pain and more) we give ourselves the ability to mine data to produce observational studies at any point. From the results of these studies we can then look to demonstrate cause and effect by developing the appropriate prospective clinical trials.

As clinical trials begin to get published we will see a wave of positive changes in the industry. We are likely to begin to see cannabis coverage for patients with various medical conditions through public programs, such as OHIP in Ontario, and private insurance plans. As evidence is bolstered, we will likely see a greater adoption of prescribing from more practitioners. We will also likely see rapid pharmaceuticalization of cannabinoids into standardized products and delivery methods. We anticipate current pharmaceutical companies will be interested in this research and begin testing novel synthetic drugs that target the body’s endocannabinoid system. Ultimately, we hope through our research we will alleviate pain and suffering for millions of patients globally, increase quality of life and decrease disability. The next wave of growth in the cannabis industry is clinical research and big data and Canabo plans to be a global leader on this front.